We rely on peer-reviewed scientific research to determine what’s truly effective. Our goal is to provide clear, unbiased information to help you make better health decisions.
We use AI tools to help summarize studies, and every piece of content is reviewed and approved by qualified experts, ensuring it’s accurate and trustworthy.
Beta Glucan is fully independent — we don’t sell products, run ads, or accept sponsorships. Our only focus is delivering reliable, science-backed insights.
Key study details
Objective
To evaluate the efficacy and safety of a nasal solution containing resveratrol and carboxymethyl-β-glucan in reducing wheezing episodes and severity in preschool non-atopic children with recurrent wheezing triggered by upper respiratory tract infections (URTIs).
Methods
- Design: Prospective, single-blind, placebo-controlled study.
- Participants: 42 preschool children (<6 years) with ≥8 wheezing episodes in the prior 6 months, negative skin prick tests, and no background corticosteroid or montelukast therapy.
- Intervention:
- Active group: Daily saline nasal lavage plus a 7-day course of nasal solution containing resveratrol (0.05%) and carboxymethyl-β-glucan (0.33%) at URTI onset, administered 4 times/day.
- Placebo group: Daily saline nasal lavage only.
- Follow-up: Six months, with symptom diaries tracking URTI and wheezing episodes, oral corticosteroid (OCS) use, and hospitalizations.
Results
- URTI Episodes: No significant difference in frequency between groups.
- Wheezing Episodes:
- Placebo group: 86 episodes; median 3.89 episodes/patient; 2.1 days/month.
- Active group: 23 episodes; median 1.29 episodes/patient; 0.5 days/month (p < 0.001).
- Severity Index:
- Hospitalization days: 18 (placebo) vs. 1 (active) (p < 0.001).
- OCS days: 53 (placebo) vs. 10 (active) (p < 0.01).
- Mean severity days/month: 0.6 (placebo) vs. 0.1 (active) (p < 0.01).
- Safety: No serious adverse events. Mild nasal irritation occurred more frequently in the active group but resolved spontaneously.
Our take
Interpretation
The nasal solution combining resveratrol and carboxymethyl-β-glucan significantly reduced the frequency and severity of wheezing episodes in non-atopic preschool children with URTI-induced wheezing. Mechanistically, resveratrol’s anti-inflammatory and antiviral effects—mediated via NF-κB inhibition and cytokine modulation—combined with β-glucan’s immune-enhancing activity through pattern recognition receptors (e.g., Dectin-1, TLRs), likely contributed to the observed benefits.
Limitations
- Small sample size (n = 39 completed).
- Single-blind design may introduce bias.
- Intermittent rather than continuous treatment.
- No biomarker or microbiome analysis to confirm mechanisms.
- Findings limited to non-atopic children.
Implications
This study explored the resveratrol plus carboxymethyl-β-glucan nasal solution as a safe adjunctive therapy to reduce wheezing burden in preschool children with viral-induced wheezing. It offers a promising non-pharmacologic strategy to complement standard care and reduce reliance on corticosteroids and hospital resources.
This summary is based on peer-reviewed scientific research. We use AI tools to help condense complex studies, but all content is reviewed and approved by qualified experts before publication.
Citation
Copied!